Fifth Third Bancorp’s Stoke Therapeutics STOK Stock Holding History

Fifth Third Bancorp’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.61K	Buy	+62	New	+$1.87K	﹤0.01%	4119

Other funds holding STOK

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Fifth Third Bancorp's STOK Position: Q3 2026 in Review

Fifth Third Bancorp opened a new position in Stoke Therapeutics (STOK) in Q3 2026: 62 shares worth $1.61K. The stake represents ﹤0.01% of the portfolio and ranks #4119 among its holdings.

74 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

Fifth Third Bancorp held 62 shares of Stoke Therapeutics worth $1.61K as of Q3 2026.
Stoke Therapeutics was a new Fifth Third Bancorp position in Q3 2026.
Stoke Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q3 2026, its #4119 holding.
74 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on Fifth Third Bancorp's 13F filing for Q3 2026, filed 5 Nov 2026.